Scottish Diabetes Group. Scottish Diabetes Survey 2021. [Internet]. Diabetes in Scotland; 2023 Feb 15 [cited: 2023 Jun 15]. Available from: https://www.diabetesinscotland.org.uk/wp-content/uploads/2023/ 02/Diabetes-Scottish-Diabetes-Survey-2021-final-version.pdf

Yun J, Ko Seung-Hyun, Current trends in epidemiology in cardiovascular disease and cardiovascular risk management in type 2 diabetes. Metabolism 2021;123:154838. https://doi.org/10.1016/j.metabol.2021.154838

Zinman B, Wanner C, Lachin J, etal. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2016; 373:2117-28. https://doi.org/10.1056/NEJMoa1504720

Wiviott S, Raz I, Bonaca M, etal. Dapagliflozin and cardiovascular outcome in type 2 diabetes. N Engl J Med 2019;380:347-57. https://doi.org/10.1056/NEJMoa1812389

Neal B, Perkovic V, Mahaffey K, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-57. https://doi.org/10.1056/NEJMoa1611925

Type 2 diabetes management in adults: management [Internet]. 2022 [Cited 2023 Jun 15]. Available from: https://www.nice.org.uk/guidance/ng28

SIGN 154: Pharmacological management of glycaemic control in people with type 2 diabetes mellitus. www.sign.ac.uk

Kansal A, Reifsnider, Proskorovsky I, et al. Cost-effectiveness analysis of empagliflozin treatment in people with T2DM and established cardiovascular disease in the EMPA-REG OUTCOME trial. Diabet Med 2019;36(11):1494-502. https://doi.org/10.1111/dme.14076

Public Health Scotland. General Practice – GP workforce and practice list sizes [Internt]. Public Health Scotland; 2022 Dec 13 [cited date – 2023 Jul 4]. Available from: https://publichealthscotland.scot/publications/general-practice-gp-workforce-and-practice-list-sizes/general-practice-gp-workforce-and-practice-list-sizes-2012-2022/

National Therapeutics Indicators [Internet]. 2023[Cited 2023 Jun 15]. Available from: https://scotland.shinyapps.io/nhs-prescribing-nti/